Table 1.

Categorization of cytotoxic chemotherapies received during the study period

Category A	Category B
5-Fluorouracil	Capecitabine
Epirubicin	Docetaxel
Doxorubicin	Gemcitabine
Cyclophosphamide	Ixabepilone
Etoposide	Liposomal doxorubicin
Ifosfamide	Nab-paclitaxel
Methotrexate	Paclitaxel
Cisplatin	Vinorelbine
Carboplatin

Novel agents were considered to be those approved since 1994 and are listed in Category B, while other available agents are included in Category A.